Satellos Bioscience Inc

Healthcare CA MSCL

0.56CAD
0.01(1.82%)

Last update at 2024-02-14T20:08:00Z

Day Range

0.560.58

LowHigh

52 Week Range

0.260.85

LowHigh

Fundamentals

Previous Close 0.55
Market Cap54.70M
Volume53750
P/E Ratio-
Dividend Yield-%
EBITDA-11.40467M
Revenue TTM-0.05000M
Revenue Per Share TTM-0.002
Gross Profit TTM -0.06763M
Diluted EPS TTM-0.25

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Income before tax	-11.31682M	-15.50565M	-1.57853M	-
Minority interest	-	-	-	-
Net income	-11.32244M	-15.50565M	-1.57853M	-
Selling general administrative	5.44M	2.60M	0.90M	-
Selling and marketing expenses	-	-	-	-
Gross profit	-	-0.11992M	-0.04816M	-
Reconciled depreciation	0.34M	0.17M	0.00042M	-
Ebit	-8.37862M	-4.76761M	-1.57100M	-1.99954M
Ebitda	-10.97987M	-4.49460M	-1.47479M	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	-8.37862M	-4.66029M	-1.47521M	-
Other operating expenses	-	-	-	-
Interest expense	0.00000M	0.99M	0.02M	0.00000M
Tax provision	0.00562M	-	-	-
Interest income	0.02M	0.00799M	0.00497M	-
Net interest income	0.02M	-0.92621M	-0.01261M	-
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	0.00562M	-	-	-
Total revenue	0.00000M	0.00000M	0.00000M	-
Total operating expenses	8.38M	4.66M	1.48M	-
Cost of revenue	-	0.12M	0.05M	-
Total other income expense net	-2.95883M	-9.91915M	-0.09071M	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-11.32244M	-15.50565M	-1.57853M	-
Net income applicable to common shares	-11.32244M	-15.50565M	-1.57853M	-1.98845M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total assets	6.20M	12.59M	1.13M	-
Intangible assets	3.92M	7.14M	-	-
Earning assets	-	-	-	-
Other current assets	0.00298M	-	-	-
Total liab	2.83M	2.10M	1.31M	-
Total stockholder equity	3.37M	10.48M	-0.18384M	-
Deferred long term liab	-	-	-	-
Other current liab	-	-	0.02M	0.03M
Common stock	30.21M	28.32M	4.36M	3.46M
Capital stock	30.21M	28.32M	4.36M	-
Retained earnings	-31.61370M	-20.29126M	-4.78561M	-3.20708M
Other liab	-	-	-	-
Good will	-	-	-	-
Other assets	-	-	-	-
Cash	1.92M	4.87M	0.72M	-
Cash and equivalents	-	-	-	-
Total current liabilities	2.83M	2.10M	0.22M	0.66M
Current deferred revenue	-	-	-	-
Net debt	-	-	0.38M	-
Short term debt	-	-	-	-
Short long term debt	-	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	2.10M	1.22M	-	-
Property plant equipment	0.00804M	0.00819M	0.00169M	0.00211M
Total current assets	2.23M	5.44M	1.13M	1.07M
Long term investments	0.04M	-	-	-
Net tangible assets	-0.54767M	3.35M	-0.18384M	0.41M
Short term investments	-	-	-	-
Net receivables	0.26M	0.53M	0.41M	0.66M
Long term debt	-	-	1.09M	-
Inventory	-	-	-	-
Accounts payable	1.47M	1.13M	0.13M	0.63M
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	3.97M	7.14M	0.00169M	-
Capital lease obligations	-	-	-	-
Long term debt total	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Investments	-0.00347M	1.74M	0.00000M	-
Change to liabilities	0.73M	-0.39047M	-0.44485M	0.48M
Total cashflows from investing activities	-0.00347M	1.74M	1.74M	-0.00077M
Net borrowings	-	0.19M	1.09M	1.09M
Total cash from financing activities	2.77M	7.45M	1.98M	1.16M
Change to operating activities	0.26M	-0.13529M	0.29M	-0.44153M
Net income	-11.32244M	-15.50565M	-1.57853M	-1.98845M
Change in cash	-2.94773M	4.15M	0.32M	-0.76794M
Begin period cash flow	4.87M	0.72M	0.40M	-
End period cash flow	1.92M	4.87M	0.72M	0.40M
Total cash from operating activities	-5.71335M	-5.03371M	-1.65998M	-1.92444M
Issuance of capital stock	2.00M	0.40M	0.89M	-
Depreciation	0.34M	0.17M	0.00042M	0.00073M
Other cashflows from investing activities	-	-	-	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	0.00178M	0.04M	-0.02941M	-0.01250M
Sale purchase of stock	-	-	-	-
Other cashflows from financing activities	0.78M	0.78M	0.78M	0.78M
Change to netincome	4.28M	10.79M	0.10M	0.04M
Capital expenditures	0.00347M	0.00725M	0.00725M	0.00077M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	0.99M	-0.48564M	-0.18292M	-
Stock based compensation	1.44M	0.97M	0.09M	-
Other non cash items	-	9.84M	0.00547M	-
Free cash flow	-5.71682M	-5.04096M	-1.65998M	-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
MSCL Satellos Bioscience Inc	0.01 1.82%	0.56	-	-	360.97	1.18	-0.5661
SHRX Sharp Therapeutics Corp.	- -%	1.00	-	-	-	32.37
NRX NurExone Biologic Inc.	-0.01 1.79%	0.55	-	6.90	-	15.26	-7.2365
MIR MedMira Inc	- -%	0.07	-	-	223.37	-	293.42	-80.0318
TTI Thiogenesis Therapeutics Corp.	- -%	0.56	-	-	-	15.17	-58.1577

Reports Covered

View All

Profile

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company's MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

65 Front Street East, Toronto, ON, Canada, M5E 1B5

647 660 1780
https://satellos.com

Key Executives

Name	Title	Year Born
Mr. Francis Gleeson B.B.A. M.B.A	Co-Founder, CEO, Pres & Director	1955
Dr. Michael A. Rudnicki Ph.D.	Co-Founder & Chief Scientific Officer	1961
Mr. Warren Whitehead C.M.A., CPA	Chief Financial Officer	1952
Mr. William Wasyl Jarosz	Exec. Director	1956
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA	Strategic Advisor	1960
Dr. Philip Lambert M.A., Ph.D.	Chief Technology Officer	1968
Mr. J. Robert Hall CFA	VP of Fin. & Admin.	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.